Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis-Reference-Cited by-同舟云学术

Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis

Published:2015-11-23 Issue:3 Volume:154 Page:591-608
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Adunlin George,Cyrus John W. W.,Dranitsaris George

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-015-3643-5.pdf

Reference22 articles.

1. Baselga J, Cortés J, Kim S et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119

2. Pierga JY, Delva R, Pivot X et al (2014) Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer: overall survival and subgroup analyses of the ATHENA study in France. Bull Cancer 101:780–788

3. Dranitsaris G, Papadopoulos G (2014) Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice? Applied Health Economics and Health Policy, pp 1–12

4. Lowes R (2011) Avastin no longer approved for breast cancer, FDA says. Medscape Web site. Avastin no longer approved for breast cancer, FDA says. Medscape Web site

5. Fojo T, Grady C (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044–1048

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies;European Journal of Cancer;2024-02

2. Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials;Journal of Cancer Research and Clinical Oncology;2024-01

3. Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials;Breast Cancer Research and Treatment;2023-11-13

4. Sample size optimization for clinical trials using graphical approaches for multiplicity adjustment;Statistics in Medicine;2023-09-20

5. Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework;PharmacoEconomics;2023-07-25